Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials
Frontiers in Pharmacology · 13.06.2023 · 14
DOI: 10.3389/fphar.2023.1158274 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.06.2023. Verfasst von Min Luo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Aims
As the impact of inclisiran in stroke prevention in atherosclerotic cardiovascular disease (ASCVD) patients or those at high risk of ASCVD is still unclear, we conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to quantify the effectiveness of inclisiran in stroke prevention in these patients.
Methods
Literature research was conducted in four electronic databases (PubMed, EMBASE, Web of Science, CENTRAL) and two clinical trials registers ( ClinicalTrials.gov , WHO ICTRP) from the inception of the study to 17 October 2022, and was updated by the end of the study on 5 January 2023. Two authors independently screened the studies, extracted the data, and assessed the bias. The risk of bias was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB 2). The intervention effect was estimated by calculating risk ratio (RR), weighted mean difference (WMD), and 95% confidence interval (CI) with R 4.0.5. Sensitivity analysis by changing meta-analysis model was also performed to test the robustness of the pooled results. If this was not possible, a descriptive analysis was conducted.
Results
Four RCTs ( n = 3,713 patients) were rated as high-risk bias. Meta-analysis of three RCTs (ORION-9, ORION-10, and ORION-11) showed that inclisiran reduced myocardial infarction (MI) risk by 32% (RR = 0.68, 95%CI = 0.48–0.96) but did not reduce stroke (RR = 0.92, 95%CI = 0.54–1.58) and major cardiovascular events (MACE) (RR = 0.81, 95%CI = 0.65–1.02) risk. Sensitivity analysis results were stable. Safety was similar to the placebo group but had frequent injection-site reactions (RR = 6.56, 95%CI = 3.83–11.25), which were predominantly mild or moderate. A descriptive analysis of one RCT (ORION-5) was conducted due to different study designs, and suggested that inclisiran might be given semiannually from the beginning.
Conclusion
Inclisiran is not beneficial for stroke or MACE prevention in ASCVD or patients at high risk of ASCVD but is associated with the reduction of MI. Given the limited number and quality of the available studies and the lack of a standardized definition for cardiovascular events, further studies are essential for confirming the results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
- West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Zitieren
APA
Luo, M., Liu, Y., Xu, X., Liu, K., Shen, C., Hu, H., He, Z., & Wu, F. (2023). Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1158274
Vancouver
Luo M, Liu Y, Xu X, Liu K, Shen C, Hu H, et al. Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1158274
BibTeX
@article{Luo2023,
author = {Luo, Min and Liu, Yihan and Xu, Xinyi and Liu, Kai and Shen, Chao and Hu, Haoyang and He, Zhiyao and Wu, Fengbo},
title = {Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1158274}
}
EUVIMED